The Glargine Insulin Market study analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments- By Drug (Lantus, Basaglar, Toujeo, Soliqua/Suliqua, Insulin Glargine Biosimilars), By Application (Type 2 Diabetes, Type 1 Diabetes).
Glargine insulin, a long-acting insulin analog, plays a pivotal role in the management of diabetes mellitus, offering consistent glycemic control and reduced risk of hypoglycemia. In 2024, the market for glargine insulin is characterized by ongoing innovation in insulin delivery devices and formulations aimed at enhancing convenience, adherence, and therapeutic outcomes for patients with diabetes. Long-acting insulin analogs with extended duration of action and ultra-long formulations are being developed to mimic physiological insulin secretion patterns more closely, improving glycemic control and reducing the burden of multiple daily injections. Furthermore, integration of digital health technologies, such as insulin pumps with continuous glucose monitoring systems and smartphone apps for insulin dose titration, is empowering patients and healthcare providers to optimize diabetes management strategies. With the global prevalence of diabetes on the rise, driven by sedentary lifestyles and obesity, the demand for safe and effective insulin therapies like glargine insulin is expected to grow, driving continued innovation in this therapeutic area.
A significant trend in the market for glargine insulin is the increasing adoption of biosimilar products. With the expiration of patents for branded glargine insulin formulations, there's a notable trend toward the development and commercialization of biosimilar versions of glargine insulin by pharmaceutical manufacturers. Biosimilars offer a cost-effective alternative to branded products, providing similar efficacy, safety, and quality while offering potential cost savings to healthcare systems and patients. This trend reflects the growing acceptance of biosimilars as viable treatment options for diabetes management, driving market competition and expanding access to glargine insulin therapy for individuals with diabetes worldwide.
The primary driver propelling the market for glargine insulin is the rising prevalence of diabetes and insulin resistance globally. With lifestyle changes, sedentary habits, and increasing obesity rates contributing to the growing incidence of type 2 diabetes, there's a corresponding increase in the demand for insulin therapy to manage blood glucose levels and prevent diabetes-related complications. Glargine insulin, with its long-acting profile and ability to provide basal insulin coverage, plays a crucial role in the treatment regimens of individuals with diabetes, driving the demand for this therapeutic agent. Additionally, the rising prevalence of insulin resistance in both type 1 and type 2 diabetes populations further fuels the need for insulin therapy, underscoring the importance of glargine insulin in diabetes management.
An untapped opportunity within the market for glargine insulin lies in the development of enhanced formulations and delivery systems. While existing glargine insulin products offer effective glycemic control, there's potential to innovate and improve upon current formulations to address unmet patient needs and optimize treatment outcomes. Manufacturers have the opportunity to explore novel formulations with extended duration of action, improved pharmacokinetics, and reduced risk of hypoglycemia, offering greater convenience and flexibility for patients. Additionally, advancements in insulin delivery systems, such as patch pumps, smart pens, and implantable devices, present opportunities to enhance insulin administration, improve treatment adherence, and enhance patient satisfaction. Embracing the opportunity to develop enhanced formulations and delivery systems for glargine insulin aligns to advance diabetes care, improves patient outcomes, and addresses the evolving needs of individuals living with diabetes.
The Insulin Glargine Biosimilars segment within the Glargine Insulin Market is experiencing rapid growth due to increasing demand for cost-effective and accessible treatment options for both type 1 and type 2 diabetes mellitus. Biosimilar insulin glargine products offer comparable efficacy, safety, and quality to the reference innovator insulin glargine (Lantus) at a lower cost, making them attractive alternatives for patients and healthcare systems worldwide. These biosimilars provide a more affordable option for insulin therapy, addressing the economic burden associated with diabetes management and improving patient access to essential diabetes medications. The availability of multiple biosimilar versions of insulin glargine, such as Abasaglar, Semglee, and others, further intensifies market competition and drives down prices, enhancing affordability and market penetration. Additionally, regulatory approvals and favorable reimbursement policies support the adoption of insulin glargine biosimilars across various healthcare settings, including hospitals, clinics, and retail pharmacies. With the rising prevalence of diabetes globally and the growing need to optimize healthcare expenditure while ensuring quality care, the Insulin Glargine Biosimilars segment is poised for significant growth in the Glargine Insulin Market, offering a cost-effective and sustainable solution for diabetes management.
The market research study provides in-depth insights into leading companies including the SWOT analyses, product profile, financial details, and recent developments acrossBiocon Ltd, Eli Lilly and Company, Julphar (Gulf Pharmaceutical Industries) PJSC, Novo Nordisk A/S, Sanofi S.A.
By Drug
Lantus
Basaglar
Toujeo
Soliqua/Suliqua
Insulin Glargine Biosimilars
By Application
Type 2 Diabetes
Type 1 Diabetes
Geographical Analysis
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)
Biocon Ltd
Eli Lilly and Company
Julphar (Gulf Pharmaceutical Industries) PJSC
Novo Nordisk A/S
Sanofi S.A.
• Deepen your industry insights and navigate uncertainties for strategy formulation, CAPEX, and Operational decisions
• Gain access to detailed insights on the Glargine Insulin Market, encompassing current market size, growth trends, and forecasts till 2030.
• Access detailed competitor analysis, enabling competitive advantage through a thorough understanding of market players, strategies, and potential differentiation opportunities
• Stay ahead of the curve with insights on technological advancements, innovations, and upcoming trends
• Identify lucrative investment avenues and expansion opportunities within the Glargine Insulin Market industry, guided by robust, data-backed analysis.
• Understand regional and global markets through country-wise analysis, regional market potential, regulatory nuances, and dynamics
• Execute strategies with confidence and speed through information, analytics, and insights on the industry value chain
• Corporate leaders, strategists, financial experts, shareholders, asset managers, and governmental representatives can make long-term planning scenarios and build an integrated and timely understanding of market dynamics
• Benefit from tailored solutions and expert consultation based on report insights, providing personalized strategies aligned with specific business needs.
TABLE OF CONTENTS
1 Introduction to 2024 Glargine Insulin Market
1.1 Market Overview
1.2 Quick Facts
1.3 Scope/Objective of the Study
1.4 Market Definition
1.5 Countries and Regions Covered
1.6 Units, Currency, and Conversions
1.7 Industry Value Chain
2 Research Methodology
2.1 Market Size Estimation
2.2 Sources and Research Methodology
2.3 Data Triangulation
2.4 Assumptions and Limitations
3 Executive Summary
3.1 Global Glargine Insulin Market Size Outlook, $ Million, 2021 to 2030
3.2 Glargine Insulin Market Outlook by Type, $ Million, 2021 to 2030
3.3 Glargine Insulin Market Outlook by Product, $ Million, 2021 to 2030
3.4 Glargine Insulin Market Outlook by Application, $ Million, 2021 to 2030
3.5 Glargine Insulin Market Outlook by Key Countries, $ Million, 2021 to 2030
4 Market Dynamics
4.1 Key Driving Forces of Glargine Insulin Industry
4.2 Key Market Trends in Glargine Insulin Industry
4.3 Potential Opportunities in Glargine Insulin Industry
4.4 Key Challenges in Glargine Insulin Industry
5 Market Factor Analysis
5.1 Value Chain Analysis
5.2 Competitive Landscape
5.2.1 Global Glargine Insulin Market Share by Company (%), 2023
5.2.2 Product Offerings by Company
5.3 Porter’s Five Forces Analysis
5.4 Pricing Analysis and Outlook
6 Growth Outlook Across Scenarios
6.1 Growth Analysis-Case Scenario Definitions
6.2 Low Growth Scenario Forecasts
6.3 Reference Growth Scenario Forecasts
6.4 High Growth Scenario Forecasts
7 Global Glargine Insulin Market Outlook by Segments
7.1 Glargine Insulin Market Outlook by Segments, $ Million, 2021- 2030
By Drug
Lantus
Basaglar
Toujeo
Soliqua/Suliqua
Insulin Glargine Biosimilars
By Application
Type 2 Diabetes
Type 1 Diabetes
8 North America Glargine Insulin Market Analysis and Outlook To 2030
8.1 Introduction to North America Glargine Insulin Markets in 2024
8.2 North America Glargine Insulin Market Size Outlook by Country, 2021-2030
8.2.1 United States
8.2.2 Canada
8.2.3 Mexico
8.3 North America Glargine Insulin Market size Outlook by Segments, 2021-2030
By Drug
Lantus
Basaglar
Toujeo
Soliqua/Suliqua
Insulin Glargine Biosimilars
By Application
Type 2 Diabetes
Type 1 Diabetes
9 Europe Glargine Insulin Market Analysis and Outlook To 2030
9.1 Introduction to Europe Glargine Insulin Markets in 2024
9.2 Europe Glargine Insulin Market Size Outlook by Country, 2021-2030
9.2.1 Germany
9.2.2 France
9.2.3 Spain
9.2.4 United Kingdom
9.2.4 Italy
9.2.5 Russia
9.2.6 Norway
9.2.7 Rest of Europe
9.3 Europe Glargine Insulin Market Size Outlook by Segments, 2021-2030
By Drug
Lantus
Basaglar
Toujeo
Soliqua/Suliqua
Insulin Glargine Biosimilars
By Application
Type 2 Diabetes
Type 1 Diabetes
10 Asia Pacific Glargine Insulin Market Analysis and Outlook To 2030
10.1 Introduction to Asia Pacific Glargine Insulin Markets in 2024
10.2 Asia Pacific Glargine Insulin Market Size Outlook by Country, 2021-2030
10.2.1 China
10.2.2 India
10.2.3 Japan
10.2.4 South Korea
10.2.5 Indonesia
10.2.6 Malaysia
10.2.7 Australia
10.2.8 Rest of Asia Pacific
10.3 Asia Pacific Glargine Insulin Market size Outlook by Segments, 2021-2030
By Drug
Lantus
Basaglar
Toujeo
Soliqua/Suliqua
Insulin Glargine Biosimilars
By Application
Type 2 Diabetes
Type 1 Diabetes
11 South America Glargine Insulin Market Analysis and Outlook To 2030
11.1 Introduction to South America Glargine Insulin Markets in 2024
11.2 South America Glargine Insulin Market Size Outlook by Country, 2021-2030
11.2.1 Brazil
11.2.2 Argentina
11.2.3 Rest of South America
11.3 South America Glargine Insulin Market size Outlook by Segments, 2021-2030
By Drug
Lantus
Basaglar
Toujeo
Soliqua/Suliqua
Insulin Glargine Biosimilars
By Application
Type 2 Diabetes
Type 1 Diabetes
12 Middle East and Africa Glargine Insulin Market Analysis and Outlook To 2030
12.1 Introduction to Middle East and Africa Glargine Insulin Markets in 2024
12.2 Middle East and Africa Glargine Insulin Market Size Outlook by Country, 2021-2030
12.2.1 Saudi Arabia
12.2.2 UAE
12.2.3 Oman
12.2.4 Rest of Middle East
12.2.5 Egypt
12.2.6 Nigeria
12.2.7 South Africa
12.2.8 Rest of Africa
12.3 Middle East and Africa Glargine Insulin Market size Outlook by Segments, 2021-2030
By Drug
Lantus
Basaglar
Toujeo
Soliqua/Suliqua
Insulin Glargine Biosimilars
By Application
Type 2 Diabetes
Type 1 Diabetes
13 Company Profiles
13.1 Company Snapshot
13.2 SWOT Profiles
13.3 Products and Services
13.4 Recent Developments
13.5 Financial Profile
List of Companies
Biocon Ltd
Eli Lilly and Company
Julphar (Gulf Pharmaceutical Industries) PJSC
Novo Nordisk A/S
Sanofi S.A.
14 Appendix
14.1 Customization Offerings
14.2 Subscription Services
14.3 Related Reports
14.4 Publisher Expertise
By Drug
Lantus
Basaglar
Toujeo
Soliqua/Suliqua
Insulin Glargine Biosimilars
By Application
Type 2 Diabetes
Type 1 Diabetes
Countries Analyzed
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)
The global Glargine Insulin Market is one of the lucrative growth markets, poised to register a 6.5% growth (CAGR) between 2024 and 2030.
Emerging Markets across Asia Pacific, Europe, and Americas present robust growth prospects.
Biocon Ltd, Eli Lilly and Company, Julphar (Gulf Pharmaceutical Industries) PJSC, Novo Nordisk A/S, Sanofi S.A.
Base Year- 2023; Estimated Year- 2024; Historic Period- 2018-2023; Forecast period- 2024 to 2030; Currency: USD; Volume